共 151 条
[1]
Black DM(1996)Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet Lond Engl 348 1535-1541
[2]
Cummings SR(2000)Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118-4124
[3]
Karpf DB(1999)Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637-645
[4]
Cauley JA(2004)The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459-468
[5]
Thompson DE(2009)Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study J Bone Miner Res Off J Am Soc Bone Miner Res 24 719-725
[6]
Nevitt MC(2005)Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res Off J Am Soc Bone Miner Res 20 1315-1322
[7]
Black DM(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441
[8]
Thompson DE(2008)Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 CD001155-13
[9]
Bauer DC(2008)Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 CD004523-216
[10]
Ensrud K(2009)Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3-242